Binding to CD20 by anti-B1 antibody or F(ab')2 is sufficient for induction of apoptosis in B-cell lines

Cancer Immunology, Immunotherapy

Volumn 51, Issue 1, 2002, Pages 15-24

  Cardarelli, Pina M ^a   Maire, Quinn ^a   Dana, Buckman ^a   Yu, Fang ^a   David, Colcher ^a   King, David J ^a   Christopher, Bebbington ^a   Geoffrey, Yarranton ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Anti B1 Antibody; Antibody therapy; Apoptosis; CD20; Rituximab

Indexed keywords

CD20 ANTIGEN; CD59 ANTIGEN; DECAY ACCELERATING FACTOR; IMMUNOGLOBULIN F(AB')2 FRAGMENT; RITUXIMAB; TOSITUMOMAB;

ANTIBODY AFFINITY; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN BINDING; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; B CELL LEUKEMIA; B CELL LYMPHOMA; CELL ASSAY; COMPLEMENT DEPENDENT CYTOTOXICITY; CONTROLLED STUDY; CROSS LINKING; DIMERIZATION; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; HUMAN; HUMAN CELL; LEUKOCYTE; LYMPHOMA CELL; PRIORITY JOURNAL;

ANIMALS; ANNEXIN A5; ANTIBODIES, MONOCLONAL; ANTIBODY SPECIFICITY; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD20; ANTIGENS, CD55; ANTIGENS, CD59; ANTIGENS, NEOPLASM; APOPTOSIS; B-LYMPHOCYTES; BURKITT LYMPHOMA; COMPLEMENT SYSTEM PROTEINS; CYTOTOXICITY, IMMUNOLOGIC; DIMERIZATION; GOATS; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; IMMUNOGLOBULIN FC FRAGMENTS; IMMUNOGLOBULIN G; LEUKEMIA, B-CELL, ACUTE; LYMPHOMA, B-CELL; MICE; NEOPLASM PROTEINS; TUMOR CELLS, CULTURED;

EID: 0036179899     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-001-0247-1     Document Type: Article

References (31)

1. Comparison of the effector functions of human immunoglobulins using a matched set of chimeric antibodies
2. Complement activation in heart diseases. Role of oxidants
3. CD20: A review
4. Recent advances in antigen-targeted therapy in non-Hodgkin's lymphoma
5. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetra-chloro-3a,6a-diphenylglycoluril
6. A non-radioactive complement-dependent cytotoxicity assay for anti-CD20 monoclonal antibody
7. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemother-apeutic agent and an immunotoxin
8. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis
9. Risk factors for side effects during first infusion of rituximab-definition of a low risk group
10. Rituximab (anti-CD20) therapy of B-cell lymphomas: Direct complement killing is superior to cellular effector mechanisms
11. Clustered CD20 induced apoptosis: Src-family kinase, the proximal regulator of tyrosine phosphorylation, calcium influx, and caspase 3-dependent apoptosis
12. Engagement of CD20 suppresses apoptosis in germinal center B cells
13. Iodine-131 tositumomab for non-Hodgkin's lymphoma (NHL) patients who progressed after treatment with rituximab: Results of a multi-center Phase II study
14. Effector mechanisms activated by human IgG subclass antibodies: Clinical and molecular aspects
15. Iodine I-131 tositumomab therapy for previously untreated follicular lymphoma
16. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience
17. Pivotal study of iodine I131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin
18. Randomized controlled study of Iodine-131 Anti-B1 Antibody vs unlabeled Anti-B1 Antibody in patients with chemotherapy refractory low-grade non-Hodgkin's lymphoma
19. Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis
20. Use of rituximab, the new FDA-approved antibody
21. The interaction of murine IgG subclass proteins with human monocyte Fc receptors
22. Anti-CD20- and B-cell receptor-mediated apoptosis: Evidence for shared intracellular signaling pathways
23. Methods for detecting and quantifying apoptosis
24. Apoptosis detection: An overview
25. Apoptosis of malignant human B cells by ligation of CD20 with monoclonal antibodies
26. Signaling events involved in anti-CD20-induced apoptosis of malignant human B cells
27. Characterization of a human B lymphocyte-specific antigen
28. Growth inhibition of CD20-positive B lymphoma cell lines by IDEC-C2B8 anti-CD20 monoclonal antibody
29. The B cell surface molecule B1 is functionally linked with B cell activation and differentiation
30. Antibodies reactive with the B1 molecule inhibit cell cycle progression but not activation of human B lymphocytes
31. Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non- Hodgkin's lymphomas